University of Perugia — Publications

Early Recurrence and Cerebral Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation

Article

Background and Purpose— The best time for administering anticoagulation therapy in acute cardioembolic stroke remains unclear. This prospective cohort study of patients with acute stroke and atrial fibrillation, evaluated (1) the risk of recurrent ischemic event and severe bleeding; (2) the risk factors for recurrence and bleeding; and (3) the risks of recurrence and bleeding associated with anticoagulant therapy and its starting time after the acute stroke. Methods— The primary outcome of this multicenter study was the composite of stroke, transient ischemic attack, symptomatic systemic embolism, symptomatic cerebral bleeding and major extracranial bleeding within 90 days from acute stroke. Results— Of the 1029 patients enrolled, 123 had 128 events (12.6%): 77 (7.6%) ischemic stroke or transient ischemic attack or systemic embolism, 37 (3.6%) symptomatic cerebral bleeding, and 14 (1.4%) major extracranial bleeding. At 90 days, 50% of the patients were either deceased or disabled (modified Rankin score ≥3), and 10.9% were deceased. High CHA 2 DS 2 -VASc score, high National Institutes of Health Stroke Scale, large ischemic lesion and type of anticoagulant were predictive factors for primary study outcome. At adjusted Cox regression analysis, initiating anticoagulants 4 to 14 days from stroke onset was associated with a significant reduction in primary study outcome, compared with initiating treatment before 4 or after 14 days: hazard ratio 0.53 (95% confidence interval 0.30–0.93). About 7% of the patients treated with oral anticoagulants alone had an outcome event compared with 16.8% and 12.3% of the patients treated with low molecular weight heparins alone or followed by oral anticoagulants, respectively ( P =0.003). Conclusions— Acute stroke in atrial fibrillation patients is associated with high rates of ischemic recurrence and major bleeding at 90 days. This study has observed that high CHA 2 DS 2 -VASc score, high National Institutes of Health Stroke Scale, large ischemic lesions, and type of anticoagulant administered each independently led to a greater risk of recurrence and bleedings. Also, data showed that the best time for initiating anticoagulation treatment for secondary stroke prevention is 4 to 14 days from stroke onset. Moreover, patients treated with oral anticoagulants alone had better outcomes compared with patients treated with low molecular weight heparins alone or before oral anticoagulants.

Publications

Early Recurrence and Cerebral Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation

GUIDELINES ON THE DIAGNOSIS AND MANAGEMENT OF ACUTE PULMONARY EMBOLISM

Deep-vein thrombosis in Europe — Burden of illness in relationship to healthcare resource utilization and return to work

Reply to Letter

Prognostic relevance of an asymptomatic venous thromboembolism in patients with cancer

Novel oral anticoagulants for patients with venous thromboembolism and active cancer: a systematic review and meta-analysis

Guidelines on the diagnosis and management of acute pulmonary embolism

Outcome in Patients with Stroke Associated with Internal Carotid Artery Occlusion

Risk assessment for recurrence and optimal agents for extended treatment of venous thromboembolism

TREATMENT AND OUTCOMES OF PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION ACCORDING TO GUIDELINE-DEFINED ANTICOAGULATION THRESHOLDS: RESULTS FROM THE GARFIELD-AF REGISTRY

Clinically relevant non-major bleeding with oral anticoagulants: non-major may not be trivial.

Effect of pentoxifylline on platelet aggregation.

Prevalence of risk factors for venous thromboembolism in the Italian population: results of a cross-sectional study from the Master Registry

Defining the Role of Computed Tomographic Pulmonary Angiography in Suspected Pulmonary Embolism

Message from the Editor

Home management or hospital admission for low-risk pulmonary embolism? Clinical scores versus pragmatic assessment

High-Sensitivity Cardiac Troponin T Elevation and Paroxysmal Supraventricular Tachycardia. Is it Always Acute Coronary Syndrome?

Long-term risk of recurrence after discontinuing anticoagulants for a first unprovoked venous thromboembolism: protocol for a systematic review and meta-analysis

Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for pulmonary embolism

Obituary J. W. ten Cate